FDA Has 19 Applications Remaining With User Fees In 2004: 7 NMEs, 1 BLA
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
With seven first-cycle new molecular entities with user fee deadlines in November and December, FDA could surpass the total number of new molecular entities approved in 2003.
You may also be interested in...
Yamanouchi Vaprisol “approvable”
Yamanouchi's Vaprisol (conivaptan) is "approvable" Nov. 30; FDA is requesting additional safety data for the hyponatremia agent. Discussions with the agency are ongoing but the company has not specified a timeframe for complete response. A September review by FDA's Endocrinologic & Metabolic Drugs Advisory Committee was cancelled. Vaprisol qualified for a priority review, but Yamanouchi opted for a standard review to allow time for the advisory committee to take place (1Pharmaceutical Approvals Monthly Nov. 1, 2004, p. 3)...
Yamanouchi Vaprisol “approvable”
Yamanouchi's Vaprisol (conivaptan) is "approvable" Nov. 30; FDA is requesting additional safety data for the hyponatremia agent. Discussions with the agency are ongoing but the company has not specified a timeframe for complete response. A September review by FDA's Endocrinologic & Metabolic Drugs Advisory Committee was cancelled. Vaprisol qualified for a priority review, but Yamanouchi opted for a standard review to allow time for the advisory committee to take place (1Pharmaceutical Approvals Monthly Nov. 1, 2004, p. 3)...
Duloxetine Drug Interactions Are Issue For Yentreve, But Not For Cymbalta
Review documents for Cymbalta note a difference in opinion regarding the significance of drug interactions between FDA’s review divisions for the two duloxetine indications – major depressive disorder and stress urinary incontinence (under the trade name Yentreve).